tert-Butyl 5-(6-Bromo-4-methyl-3-oxo-3,4-dihydropyrazin-2-ylamino)isoindoline-2-carboxylate → 5-Bromo-3-(isoindolin-5-ylamino)-1-methylpyrazin-2(1H)-one
Reaction equation
C(OCC1C(N2CCN3C4CCCCC=4C=C3C2=O)=CC(F)=CC=1C1N=C(NC2C=C3C(=CC=2)CNCC3)C(=O)N(C)C=1)(=O)C.[Br:46][C:47]1[N:52]=[C:51]([NH:53][C:54]2[CH:55]=[C:56]3[C:60](=[CH:61][CH:62]=2)[CH2:59][N:58](C(OC(C)(C)C)=O)[CH2:57]3)[C:50](=[O:70])[N:49]([CH3:71])[CH:48]=1>>[Br:46][C:47]1[N:52]=[C:51]([NH:53][C:54]2[CH:55]=[C:56]3[C:60](=[CH:61][CH:62]=2)[CH2:59][NH:58][CH2:57]3)[C:50](=[O:70])[N:49]([CH3:71])[CH:48]=1Participants
3
Reactant 2
Product 1
Procedure
Following the procedures as described for 129b and starting with 460 mg of tert-butyl 5-(6-bromo-4-methyl-3-oxo-3,4-dihydropyrazin-2-ylamino)isoindoline-2-carboxylate, 231e was obtained as a yellow solid (352 mg, 99%). MS: [M+H]+ 321
Sources & evidence
- ORD record
- ord-f29e281c269c448d9220647c342fad43
- Source dataset
- uspto-grants-2013_12
- Patent number
- US08618107B2
Reaction notes
Loading…